Aurobindo Pharma falls on US FDA OAI at Lannett

Aurobindo Pharma fell 1.26% by 2 pm on 12 Nov 2026 after the US FDA classified its Lannett facility as OAI. Support is at 1,730 and resistance at 1,860. Aurobindo Pharma Limited [AUROPHARMA] extended losses for a second straight session on 12 November 2026, down 1.26% at 2 pm. The US FDA inspected Lannett Company LLC, a wholly owned step-down subsidiary, at its Seymour facility in the US from 17 to 21 August 2026 and issued four observations, which the company answered on time. The facility is now classified “Official Action Indicated” (OAI). This is the second losing session after a fresh all-time high of Rs 1,859.90. Profit booking is also visible in Nifty, Sensex and the pharma sector. Price stays above the 20-day EMA at 1,730, and RSI at 63.61 has cooled. In my view, the trend stays strongly bullish and this looks like a correction while price holds above 1,730. A move above 1,860 would resume the uptrend. A close below 1,730 would weaken the setup, with the OAI news flow adding pressure. Stance: strongly bullish with a correction under way, and 1,730 as key support. Disclaimer: I do not hold any position in this. This content is for informational purposes only and is not a recommendation to buy or sell. Investments in securities are subject to market risks. Please read all related documents carefully before investing.